Literature DB >> 17696244

Controversies in and challenges to our understanding of hepatitis C.

Robert G Batey1.   

Abstract

Discovered in 1989, the hepatitis C virus (HCV) continues to cause significant morbidity and mortality world-wide despite a huge research commitment to defining and understanding the virus and the disease it causes. This paper discusses a number of areas where progress in the management of the HCV have not kept pace with the scientific understanding of the HCV. It is suggested that in the fields of HCV prevention and providing access to treatment, practice falls short of what could be achieved. The role of alcohol in the pathogenesis of HCV liver injury is discussed. Discrimination against those with HCV infection and particularly those in prison settings fails to match good clinical practice. The complicated processes of sharing information between specialty groups is also discussed in an attempt to optimise knowledge dissemination in this field.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17696244      PMCID: PMC4250614          DOI: 10.3748/wjg.v13.i31.4168

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  122 in total

1.  Descriptive epidemiology of hepatitis C virus among male heroin abusers in Taiwan.

Authors:  Kuan-Fu Liao; Chen-Yuang Peng; Shih-Wei Lai; Wu-Long Chang; Nan-Yung Hsu
Journal:  South Med J       Date:  2006-04       Impact factor: 0.954

2.  Treatment of hepatitis C infection in injection drug users.

Authors:  M Backmund; K Meyer; M Von Zielonka; D Eichenlaub
Journal:  Hepatology       Date:  2001-07       Impact factor: 17.425

3.  Prevalence of hepatitis C virus infection and its related risk factors in drug abuser prisoners in Hamedan--Iran.

Authors:  Amir Houshang Mohammad Alizadeh; Seyed Moayed Alavian; Khalil Jafari; Nastaran Yazdi
Journal:  World J Gastroenterol       Date:  2005-07-14       Impact factor: 5.742

4.  Managing chronic hepatitis C acquired through intravenous drug use.

Authors:  S L Jowett; K Agarwal; B C Smith; W Craig; M Hewett; D R Bassendine; E Gilvarry; A D Burt; M F Bassendine
Journal:  QJM       Date:  2001-03

5.  Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium.

Authors: 
Journal:  J Viral Hepat       Date:  1999-01       Impact factor: 3.728

6.  Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection.

Authors:  Johan Westin; L M Lagging; F Spak; N Aires; E Svensson; M Lindh; A P Dhillon; G Norkrans; R Wejstål
Journal:  J Viral Hepat       Date:  2002-05       Impact factor: 3.728

7.  Eligibility for treatment of hepatitis C virus infection among young injection drug users in 3 US cities.

Authors:  Holly Hagan; Mary H Latka; Jennifer V Campbell; Elizabeth T Golub; Richard S Garfein; David A Thomas; Farzana Kapadia; Steffanie A Strathdee
Journal:  Clin Infect Dis       Date:  2006-01-20       Impact factor: 9.079

8.  Hepatitis C virus infection among prisoners in the California state correctional system.

Authors:  Rena K Fox; Sue L Currie; Jennifer Evans; Teresa L Wright; Leslie Tobler; Bruce Phelps; Michael P Busch; Kimberly A Page-Shafer
Journal:  Clin Infect Dis       Date:  2005-06-09       Impact factor: 9.079

9.  Long-term follow-up of interferon monotherapy in 454 consecutive naive patients infected with hepatitis C virus: multi-course interferon therapy may reduce the risk of hepatocellular carcinoma and increase survival.

Authors:  Norio Akuta; Fumitaka Suzuki; Yoshiyuki Suzuki; Hitomi Sezaki; Tetsuya Hosaka; Takashi Someya; Masahiro Kobayashi; Satoshi Saitoh; Yasuji Arase; Kenji Ikeda; Mariko Kobayashi; Hiromitsu Kumada
Journal:  Scand J Gastroenterol       Date:  2005-06       Impact factor: 2.423

Review 10.  Treatment of chronic hepatitis C in patients with drug dependence: time to change the rules?

Authors:  Martin Schaefer; Andreas Heinz; Markus Backmund
Journal:  Addiction       Date:  2004-09       Impact factor: 6.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.